LUPIN News Today

Lupin Ltd Share Price

LUPIN

CMP as on 03-Jul-24 2:29
₹ 1,638

icon 5.20 | 0.32%

Open
₹ 1,640
Turnover(lac)
₹ 12,423
Prev. Close
₹ 1,632.80
Day's Vol (shares)
₹ 758,397
Day's Vol (shares)
₹ 1,629.50         ₹ 1,655.00

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
Image not found

Lupin fined 40 Million Euros by EU court for anti-competitive drug deal

Lupin has already accounted for the fine in previous financial reports, ensuring no impact on the current year’s profit and loss statement.

  • 28 Jun, 2024 |
  • 4:55 PM
Article Image

European Court of Justice upholds 40 million Euro fine on Lupin

According to reports, the sanctions were imposed as a result of their participation in "pay-for-delay" arrangements from 2005 to 2007.

  • 28 Jun, 2024 |
  • 1:39 PM
Image not found

Lupin's European arm acquires Aarane and Nalcrom brands from Sanofi

This strategic move aligns with Lupin's goal of expanding its global presence in specialty areas.

  • 06 Jun, 2024 |
  • 9:20 AM
Image not found

Lupin’s Somerset facility receives 6 observations in pre-approval USFDA inspection

Lupin said the business is thoroughly reviewing the findings and would respond to the USFDA within the timeframe specified.

  • 21 May, 2024 |
  • 11:41 AM
Image not found

Lupin’s Q4 net profit up by 52% to ₹359 Crore

Profit before tax was lower in Q4 FY2024 due to an impairment charge of ₹201.3 Crore. The quarter's R&D investment totaled ₹425.5 Crore (8.7% of revenue).

  • 07 May, 2024 |
  • 10:39 AM
Image not found

Lupin's Aurangabad facility gets zero adverse observations in US FDA's latest inspection

Lupin disclosed in a regulatory filing that a meeting of the Board of Directors is scheduled for Monday, May 6, 2024, to discuss and approve the audited financial results for the quarter and year-ended March 31, 2024, and to consider recommending dividends, if applicable.

  • 24 Apr, 2024 |
  • 11:33 AM
Image not found

Lupin Launches Generic Mybetriq in US, Eyes Robust Sales Growth

Myrbetriq, a prescription medicine, is used to treat overactive bladder symptoms like frequent or urgent urination and urinary incontinence, including neurogenic detrusor overactivity (NDO) in children.

  • 22 Apr, 2024 |
  • 3:21 PM
Image not found

Lupin launches generic version of doxycycline capsules in the US

The business got Form 483 from the USFDA in March, with one observation for its Aurangabad plant, following an inspection from March 6 to March 15.

  • 10 Apr, 2024 |
  • 2:28 PM
Image not found

Lupin names Christoph Funke as new Chief Technical Officer

He will be located in Mumbai and would be in charge of Lupin's technical operations.

  • 19 Mar, 2024 |
  • 11:06 AM
Image not found

Lupin launches generic fertility drug Ganirelix Acetate in the US

It is the generic equivalent of Organon USA LLC's Ganirelix Acetate Injection, 250 mcg/0.5 mL, which is reference listed (RLD).

  • 16 Feb, 2024 |
  • 9:26 AM